Where can I buy Celldex Therapeutics (cldx) stock?
Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celldex Therapeutics' stock price today?
Where can I buy cldx shares?
Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
When is Celldex Therapeutics'next quarterly earnings announcement?
Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022. View our earnings forecast for Celldex Therapeutics. How were Celldex Therapeutics' earnings last quarter? Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings data on Tuesday, November, 9th.
See more
Is Cldx stock a good buy?
(NASDAQ:CLDX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders.
What does Celldex Therapeutics do?
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.
When was celldex founded?
Celldex Therapeutics Inc (NASDAQ:CLDX) Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
What does relay therapeutics do?
Relay Therapeutics® is creating new possibilities in drug discovery. We aim to drug the undruggable. We are advancing a pipeline of promising therapeutic candidates, with an initial focus on precision oncology and genetic disease.
Should I buy or sell Celldex Therapeutics stock right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are current...
What is Celldex Therapeutics' stock price forecast for 2022?
5 Wall Street research analysts have issued 1-year price targets for Celldex Therapeutics' stock. Their CLDX stock forecasts range from $60.00 to $...
How has Celldex Therapeutics' stock performed in 2022?
Celldex Therapeutics' stock was trading at $38.64 at the beginning of 2022. Since then, CLDX stock has decreased by 43.9% and is now trading at $21...
When is Celldex Therapeutics' next earnings date?
Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Celldex Therapeutics' earnings last quarter?
Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.49)...
When did Celldex Therapeutics' stock split? How did Celldex Therapeutics' stock split work?
Celldex Therapeutics shares reverse split on the morning of Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8t...
Who are Celldex Therapeutics' key executives?
Celldex Therapeutics' management team includes the following people: Mr. Anthony S. Marucci M.B.A. , Founder, Pres, CEO & Director (Age 60, Pay...
Who are some of Celldex Therapeutics' key competitors?
Some companies that are related to Celldex Therapeutics include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regener...
What other stocks do shareholders of Celldex Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OP...
Is Celldex Therapeutics stock a Buy, Sell or Hold?
Celldex Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 8 buy ratings, 0 hold ratings, and 0...
What was the 52-week low for Celldex Therapeutics stock?
The low in the last 52 weeks of Celldex Therapeutics stock was 21.06. According to the current price, Celldex Therapeutics is 103.70% away from the...
What was the 52-week high for Celldex Therapeutics stock?
The high in the last 52 weeks of Celldex Therapeutics stock was 57.18. According to the current price, Celldex Therapeutics is 38.20% away from the...
What are analysts forecasts for Celldex Therapeutics stock?
The 8 analysts offering price forecasts for Celldex Therapeutics have a median target of 53.13, with a high estimate of 68.00 and a low estimate of...
How much money does Celldex make?
How many shares of Celldex Therapeutics are there after the split?
How much money does Celldex Therapeutics make? Celldex Therapeutics has a market capitalization of $1.61 billion and generates $7.42 million in revenue each year. The biopharmaceutical company earns $-59,780,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis.
Stock Price Forecast
An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.
Analyst Recommendations
The 6 analysts offering 12-month price forecasts for Celldex Therapeutics Inc have a median target of 67.00, with a high estimate of 68.00 and a low estimate of 60.00. The median estimate represents a +140.06% increase from the last price of 27.91.
